Literature DB >> 3404440

Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone.

G Malfatto1, A Zaza, M Forster, B Sodowick, P Danilo, M R Rosen.   

Abstract

We compared the electrophysiologic, inotropic and antiarrhythmic properties of propafenone and two metabolites, 5-hydroxy (5-OH) propafenone and N-depropyl (N-DP) propafenone. In 18 canine Purkinje fibers with normal maximum diastolic potentials, all drugs (1 x 10(-8) to 1 x 10(-5) M) reduced action potential amplitude and duration. However, propafenone and 5-OH propafenone reduced Vmax in a use-dependent fashion at a lower concentration than N-DP propafenone. In 16 Purkinje fibers, slow response action potentials were induced by 22 mM K+ and isoproterenol, 1 x 10(-6) M. Vmax was comparably reduced by all compounds at 1 x 10(-5) M, but action potential amplitude was not affected by 5-OH propafenone. In 16 other Purkinje fibers in which automaticity at low levels of membrane potential was induced by BaCl2 (0.25 mM), only 5-OH propafenone was effective in slowing the automatic rate at therapeutic concentrations (3 micrograms/ml). In 15 guinea pig papillary muscles, all three drugs had negative inotropic effects at concentrations greater than or equal to 1 x 10(-6) M. In conscious dogs with sustained ventricular tachycardia 24 hr after infarction, we injected propafenone or a metabolite through an atrial cannula. At similar plasma levels, neither propafenone (n = 6) nor N-DP propafenone (n = 6) suppressed the arrhythmia, whereas 5-OH propafenone eliminated ventricular tachycardia in four of six dogs, and was more effective against monomorphic than polymorphic ventricular tachycardia. Hence, the two major metabolites of propafenone have important electrophysiologic effects, and 5-OH propafenone is more potent than the parent compound as a antiarrhythmic drug in the 24-hr Harris dog.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3404440

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring.

Authors:  Kosuke Doki; Yuki Shirayama; Yukio Sekiguchi; Kazutaka Aonuma; Yukinao Kohda; Masato Homma
Journal:  Eur J Clin Pharmacol       Date:  2018-08-16       Impact factor: 2.953

2.  Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.

Authors:  M Zehender; S Hohnloser; A Geibel; A Furtwängler; M Olschewski; T Meinertz; H Just
Journal:  Br Heart J       Date:  1992-06

3.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 5.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

6.  Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig.

Authors:  L Fei; J S Gill; W J McKenna; A J Camm
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

7.  Effects of propafenone on calcium current in guinea-pig ventricular myocytes.

Authors:  C Delgado; J Tamargo; D Henzel; P Lorente
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

Review 8.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

9.  Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.

Authors:  M F Fromm; S Botsch; G Heinkele; J Evers; H K Kroemer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 10.  Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Authors:  A Capucci; G Boriani
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.